Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.

@article{Yamauchi1997PredictionOR,
  title={Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein.},
  author={Hideko Yamauchi and Anne O'neill and Rebecca S. Gelman and Walter P. Carney and Donald Y. Tenney and S H{\"o}sch and Daniel F. Hayes},
  journal={Journal of clinical oncology : official journal of the American Society of Clinical Oncology},
  year={1997},
  volume={15 7},
  pages={
          2518-25
        }
}
  • H. Yamauchi, A. O'neill, +4 authors D. Hayes
  • Published 1 July 1997
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
PURPOSE Overexpression of the HER-2/c-neu/c-erbB2 proto-oncogene is associated with a worse prognosis in patients with breast cancer, perhaps due to an association of the HER-2 proto-oncogene protein with resistance to hormone and/or chemotherapy. Circulating levels of the extracellular domain (ECD) of the HER-2/c-neu-related protein (NRP) are elevated in 20% to 40% of patients with metastatic breast cancer. We investigated whether pretreatment levels of NRP predict response to hormone therapy… 
Prognostic and Predictive Impact of the HER-2/neu Extracellular Domain (ECD) in the Serum of Patients Treated with Chemotherapy for Metastatic Breast Cancer
TLDR
In patients with metastatic breast cancer participating in a trial on first-line chemotherapy, the association of serum HER-2/neu ECD with progression-free interval, survival, and response was studied and elevated levels are associated with decreased overall survival.
The Prognostic and Predictive Values of ECD-HER-21 Commentary re : Circulating HER-2 / erbB2 / c-neu ( HER-2 ) Extracellular Domain as a Prognostic Factor in Patients with Metastatic Breast Cancer : Cancer and Leukemia Group B Study
The search for a simple, sensitive test to reliably determine prognosis and predict response to therapy in patients with cancer is an important area of translational research. In this issue of
Circulating HER 2 Extracellular Domain and Resistance to Chemotherapy in Advanced Breast Cancer 1
To test the hypothesis of an association between HER2 and chemotherapy resistance, we performed a prospective assessment of the predictive value of the circulating HER2 extracellular domain (ECD) in
Potential clinical utility of serum HER-2/neu oncoprotein concentrations in patients with breast cancer.
TLDR
The monitoring of circulating HER-2/neu ECD provides a tool for assessing prognosis, for predicting response to therapy, and for earlier detection of disease progression and timely intervention with appropriate therapy.
Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662.
TLDR
ECD/her-2 levels are elevated in 35-40% of patients with metastatic breast cancer and are associated with a poorer prognosis in these patients, but no predictive role for ECD/HER-2 was identified, either for endocrine therapy or for anthracycline-based chemotherapy in the metastatic setting.
Circulating HER2 extracellular domain and resistance to chemotherapy in advanced breast cancer.
TLDR
It is suggested that the poor response rate associated with HER2 expression in advanced breast cancer may not be reversed by aggressive chemotherapy alone, and elevated levels of circulating HER2 ECD in patients with metastatic breast cancer correlate with reduced efficacy of a paclitaxel-doxorubicin chemotherapy combination.
The Prognostic and Predictive Values of ECD-HER-2 1 Commentary re: Circulating HER-2/erbB-2/c-neu (HER-2) Extracellular Domain as a Prognostic Factor in Patients with Metastatic Breast Cancer: Cancer and Leukemia Group B Study 8662. Clin. Cancer Res., 7: 2703-2710, 2001.
TLDR
It is reported that patients with pretreatment elevation of ECD-HER-2 had a worse prognosis than those who did not, but that there was no convincing correlation of elevated E CDH-her-2 with response to either endocrine or chemotherapy.
Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer.
  • A. Lipton, S. Ali, +9 authors J. Allard
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
TLDR
Patients with ER(+) and serum HER-2/neu-positive metastatic breast cancer are less likely to respond to hormone treatment and have a shorter duration of response than ER(+), progesterone receptor-positive, or both or ER status unknown breast cancer patients.
Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma.
TLDR
Increased pretreatment levels of HER2 ECD identify a subset of patients with more aggressive tumors and less response to CM chemotherapy, which is associated with disease progression and overall survival.
Her-2/neu as a Predictive Marker of Response to Breast Cancer Therapy
TLDR
Recent data on HER-2/neu as a predictive marker of response to breast cancer therapy are highlighted and the clinical implications are discussed and the difficulty in comparing results from different data sets due to the wide variety of reagents and technologies used to detect HER- 2/neU amplification/overexpression in clinical specimens are discussed.
...
1
2
3
4
5
...

References

SHOWING 1-9 OF 9 REFERENCES
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
TLDR
This phenomenon which the authors term receptor-enhanced chemosensitivity may provide a rationale for more selective targeting and exploitation of overexpressed growth factor receptors in cancer cells, thus leading to new strategies for clinical intervention.
Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
  • J. Baselga, D. Tripathy, +11 authors L. Norton
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
RhuMAb HER2 is well tolerated and clinically active in patients with HER2-overexpressing metastatic breast cancers that had received extensive prior therapy and justifies further evaluation of this agent.
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
TLDR
It is demonstrated that introduction of a HER-2 cDNA, converting non-overexpressing breast cancer cells to those which overexpress this receptor results in development of estrogen-independent growth which is insensitive to both estrogen and the antiestrogen, tamoxifen.
Correlations between intrinsic chemoresistance and HER-2/neu gene expression, p53 gene mutations, and cell proliferation characteristics in non-small cell lung cancer cell lines.
TLDR
Results demonstrated that high p185neu expression was correlated with chemoresistance, low S-phase fractions, and long doubling times, and by contrast, cell lines expressing relatively low levels of p 185neu were relatively chemosensitive and had higher S- phase fractions and shorter doubling times.
Type 1 receptor tyrosine kinases are differentially phosphorylated in mammary carcinoma and differentially associated with steroid receptors.
The neu/erbB-2/HER-2 proto-oncogene is amplified and/or overexpressed in up to 30% of mammary carcinomas and has been variably correlated with poor prognosis. The signaling activity of the encoded
p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair.
TLDR
Taken together, data support a direct association between p185c-erbB-2 signal transduction and inhibition of cisplatin-induced DNA repair and simultaneous treatment of SKBR-3 cells with TAb 250 and cisPlatin increased cisplati/DNA intrastrand adduct formation and delayed the rate of adduct decay.
Activation of the Estrogen Receptor Through Phosphorylation by Mitogen-Activated Protein Kinase
TLDR
The phosphorylation of the human estrogen receptor (ER) serine residue at position 118 is required for full activity of the ER activation function 1 (AF-1), which is modulated by the phosphorylated Ser118 through the Ras-MAPK cascade of the growth factor signaling pathways.
Mediation by epidermal growth factor of the estradiol-induced increase in cyclic guanosine 3',5'-monophosphate content in the rat uterus.
TLDR
Treatment of incubated uterine horns from immature or mature rats with 8 nM epidermal growth factor, exactly mimicked the effect of 1 nM estradiol on cGMP levels, supporting the concept that the uterine cG MP response to estrogens is entirely due to auto/paracrine mediation by the EGF-EGF receptor system.
Should we treat HER, too?
  • D. Hayes
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996